Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% above its 5-year average of -0.12, near the high end of its 5-year range (-0.86–0.00).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% above its 12-month average of -0.20.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
-0.20
DEBT TO EQUITY RATIO AVG 3Y
-0.17
DEBT TO EQUITY RATIO AVG 5Y
-0.12
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 770 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
MiNK Therapeutics, Inc.
Market Cap
$58.64M
Debt to Equity Ratio
0.00
TTM Avg
-0.20
3Y Avg
-0.17
5Y Avg
-0.12
Market Cap
$58.66M
Debt to Equity Ratio
0.00
TTM Avg
0.41
3Y Avg
0.41
5Y Avg
0.41
Market Cap
$58.88M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$57.32M
Debt to Equity Ratio
N/A
TTM Avg
1.49
3Y Avg
1.10
5Y Avg
0.74
Market Cap
$60.89M
Debt to Equity Ratio
0.09
TTM Avg
0.33
3Y Avg
0.30
5Y Avg
0.26
Market Cap
$60.22M
Debt to Equity Ratio
N/A
TTM Avg
0.10
3Y Avg
0.06
5Y Avg
0.05
Market Cap
$56.21M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | $58.64M | 0.00 | -0.20 | -0.17 | -0.12 |
| Boundless Bio, Inc. (BOLD)vs › | $58.66M | 0.00 | 0.41 | 0.41 | 0.41 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $58.88M | 0.02 | 0.01 | 0.01 | 0.00 |
| Adicet Bio, Inc. (ACET)vs › | $59.55M | 0.11 | 0.09 | 0.09 | 0.11 |
| PDS Biotechnology Corporation (PDSB)vs › | $57.32M | N/A | 1.49 | 1.10 | 0.74 |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.89M | 0.09 | 0.33 | 0.30 | 0.26 |
| Talphera, Inc. (TLPH)vs › | $57.09M | 0.00 | 0.60 | 0.42 | 0.42 |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.22M | N/A | 0.10 | 0.06 | 0.05 |
| OKYO Pharma Limited (OKYO)vs › | $56.21M | 0.00 | 0.00 | 0.00 | 0.00 |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.12M | 0.02 | 0.01 | 0.01 | 0.03 |
Debt/Equity
0.00
Current Ratio
1.23
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | -0.36 |
| 2025-09-30 | -0.42 |
| 2025-06-30 | -0.22 |
| 2025-03-31 | -0.23 |
| 2024-12-31 | -0.25 |
| 2024-09-30 | -0.26 |
| 2024-06-30 | -0.27 |
| 2024-03-31 | -0.21 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | -0.86 |
| 2021-06-30 | -0.83 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | -0.81 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
